tak 779 has been researched along with pyrimidinones in 1 studies
| Studies (tak 779) | Trials (tak 779) | Recent Studies (post-2010) (tak 779) | Studies (pyrimidinones) | Trials (pyrimidinones) | Recent Studies (post-2010) (pyrimidinones) |
|---|---|---|---|---|---|
| 118 | 1 | 35 | 6,059 | 604 | 2,692 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, CA; Horie, T; Horuk, R; Hull, C; Li, H; Nedjai, B; Pease, JE; Vaidehi, N; Viney, JM | 1 |
1 other study(ies) available for tak 779 and pyrimidinones
| Article | Year |
|---|---|
CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779.
Topics: Acetamides; Amides; Animals; Binding Sites; CCR5 Receptor Antagonists; Cell Line; Chemotaxis; Mice; Models, Molecular; Mutagenesis, Site-Directed; Pyrimidinones; Quaternary Ammonium Compounds; Receptors, CXCR3 | 2015 |